CA1143287A - Waterproof edible encapsulation for prophylactic drugs - Google Patents
Waterproof edible encapsulation for prophylactic drugsInfo
- Publication number
- CA1143287A CA1143287A CA000383662A CA383662A CA1143287A CA 1143287 A CA1143287 A CA 1143287A CA 000383662 A CA000383662 A CA 000383662A CA 383662 A CA383662 A CA 383662A CA 1143287 A CA1143287 A CA 1143287A
- Authority
- CA
- Canada
- Prior art keywords
- capsule
- assembly according
- drug
- coating
- outer capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
Abstract
Abstract of the Disclosure The invention disclosed relates to a capsule assembly for oral administration of a prophylactic drug. The assembly includes a frangible outer capsule and an inner edible capsule of which is soluble in digestive juices. An air-space is provided between the two capsules to permit the user to bite through the outer capsule and swallow the inner capsule intact.
Description
11~3Z87 This invention relates to containers for thc oral ad~inistration of prophylactic drugs for internal medical appllcation.
It is llighly desirable that certain drugs be taken by mouth by military personnel immediately before or after they have been subjected to attack by persistent liquid nerve gas. The drugs, if taken in time, act in a prophylactic way to prevent or amcliorate poisoning by nerve agent penetrating the clothing and skin.
However, under the anticipated circumstances of chemical attack, the immediate defensive actlons of highest priority are a) to put on a protec-tive mask, b) to close all openings in protective clothing, and c) to carry out personal decontamination procedures. These actions make it e~tremely difficult or impossible to take drugs by mouth, because of the danger of con-taminating the capsules while preparing to take them in a contaminated environ-ment, while dressed in a contaminated suit and mask, and wearing heavy contam-inated protective gloves.
The alternative of having all personnel take drugs on a (4 times daily) routine basis in anticipation of attack is opc~n to serious objections, because it is likely to adversely effect the health and efficiency of the recipients, and it would be an additional unnecessary disciplinary burden to enforce compliance, unlikely to succeed completely, particularly in the absence of an immediate credible threat of chemical attack.
At present, in order to take prophylactic drugs by mouth, the seal of the mask to the face must be opened, and special precautions taken to get the dosage into the mouth without introducing contamination.
It is not certain that the present arrangement is entirely safe, and it requires considerable training.
Various alternative solutions have been proposed including providing a water-proof coated single capsule held in the mouth and swallowed at the time of detection of chemical attack. The disadvantage of this is that the waterproof coating would delay or prevent absorption of the drug. If this type '`~
~m of capsule i9 bitten open at the time of cletection of chemical attack, the drug which i9 typically in loose powder form, would be released Lnto the mouth. Difficulty in 5wallowing without water ls the obvious disadvantage.
A capsule of this type i9 described in Canadian Patent No. 315,720, which issued 29 September 1931 to G.H. Lee et al.
According to the present invention a novel capaule assembly is provided, for oral administration of a prophylactic drug, said assembly com-prising an outer capsule of a suitable edible frangible material; a substan-tially uniform coating of a suitable edible material which is insoluble in digestive juices, on the exterior of said outer capsule; an inner capsule of a suitable edible material which is soluble in digestive juices, disposed within said outer capsule and containing an appropriate unit dosage of said prophylactic drug; and an airspace between said inner and outer capsules, arranged such that when said outer capsule is broken, the inner capsule is free to be swallowed intact.
The proposal is to provide a prophylactic drug mixture which would be held in reserve within the cheek pouch continuously whlle the chemical protective ensemble is worn in the open state (i.eO garment zipper open, mask in haversack, hood open, steel helmet worn).
In response to a liquid spray attack with an unidentified chemical agent, the ensemble would be closed immediately (i.e., mask donned, zipper closed, steel helmet replaced) according to the prescribed masking drill.
The action of biting open the outer capsule and swallowing the gelatin capsule containing the drug mixture would be taken if, and only if the spray attack were identified as a nerve agent, whether by use of local detector papers, by central command based on more sophisticated detection systems, or by medical diagnosis of casualties. The biting action would take place with the protective ensemble remaining closed (mask on).
In the event of no identified nerve gas attack, the drug capsule would remain in the cheek, to be discarded and replaced by a fresh capsule at the time of unmasking or later. The presence of the capsule in the cheek does not prevent eating or drinking when unmasked.
`~
11~3Z87 In the drawing which serves to illustraLe the preferred embodiment of the invention, the fig~lre is a side elevation in section of the novel capsule assembly~
Referring specifically to the drawing, it i5 seen that the assembly comprises an outer capsule 10 of a suitable frangible edible material, inclu~
ding a tubular body portion 12 and an end closure cap 14. The outer capsule lO is sealed together by a substantially uniform coating 16 of a suitable edible materlal which is insoluble in digestive juices, on the exterior thereof. An inner capsule 18 of a suitable edible material which i8 soluble :~ 10 in digestive ~uices is provided within outer capsule 10. The inner capsule 18 contains an appropriate dosage of a prophylactic drug, typlcally in powder form. An air space 22 is provided between the inner and outer capsules and ;; is arranged such that when the outer capsule is broken by biting, the inner capgule i8 free to be swallowed intact.
Thus, the double capsule provides the drug dosage at the required time relative to the spray attack, and in a form which allows prompt and reliable absorption of the drug from the gastrointestinal tract into the blood stream.
It is important that absorption be prompt and reliable, so that the drug will arrive in the blood stream coincident with the onset of symptoms of nerve gas poisoning. For liquid nerve gas on bare skin, symptoms occur approximately 30 to 60 minutes after contact with a lethal dose.
The inner capsule, preferably made of gelatin, have two additional advantages: ta) they can be swallowed without a drink of water, which would not be immediately available to a man in a mask, and (b) the standard 2-piece gelatin capsules are readily available commercially and can be filled without access to manufacturing machinery. This enables double capsules to be made by hand quickly and cheaply.
The air space between the outer waterproof capsule and the inner gelatin capsule has two important functions: (a) it allows the gelatin capsule to emerge free of any coating, and undamaged, when the outer capsule ' .
is bitten open. The inner gelatin capA~llo i9 then ready to ~wallow wlthout water and (b) it allows sufficient clearance 80 tha~ standard commercial gelatin capsules can be loaded into the preformed outer capsule bodies by a simple hand operation.
It is intended that the outer capsule be bitten open, and the frag-ments chewed and swallowed after the inner gelatin capsule. The outer capsule must protect the inner gelatin capsule from the moisture and mechanical action of the mouth for a holding period at least equal to the maximum time expected for troops to remain masked. Ideally, the outer capsule should withstand a 12 hour holding period, and 6 hours would be the minimum acceptable. The capsules would be discarded and replaced after that time.
The outer capsule is designed intentionally to be sufficiently large, to prevent accidental swallowing without biting open.
The material of the body and cap of the outer capsule must be suffi-ciently frangible to break up on biting, to allow the inner gelatin capsule to be free to be swallowed intact. The fragments must then be chewable into small bits for swallowing, after the inner gelatin capsule has been swallowed.
The coating on the exterior surface of the outer capsule has the essential function of protecting the body of the outer capsule from the diges-tive juices in the mouth during the holding period. If this coating were not present, or if it leaks, the body of the outer capsule would disintegrate before the end of the holding period.
An additional function of the coating is to cement the cap to the body of the outer capsule. The coating material is preferably of an edible wax such as paraffin wax and beeswax. Carnauba wax is also contemplated.
; Since it has the advantage that it is recognized as being harmless when taken by mouth.
A test program has been carried out with civilian volunteer human subjects to determine:
(1) whether the prototype capsule assembly could be held in the mouth for 6 hours without interfering with normal eating and drinking;
, 11~3Z87
It is llighly desirable that certain drugs be taken by mouth by military personnel immediately before or after they have been subjected to attack by persistent liquid nerve gas. The drugs, if taken in time, act in a prophylactic way to prevent or amcliorate poisoning by nerve agent penetrating the clothing and skin.
However, under the anticipated circumstances of chemical attack, the immediate defensive actlons of highest priority are a) to put on a protec-tive mask, b) to close all openings in protective clothing, and c) to carry out personal decontamination procedures. These actions make it e~tremely difficult or impossible to take drugs by mouth, because of the danger of con-taminating the capsules while preparing to take them in a contaminated environ-ment, while dressed in a contaminated suit and mask, and wearing heavy contam-inated protective gloves.
The alternative of having all personnel take drugs on a (4 times daily) routine basis in anticipation of attack is opc~n to serious objections, because it is likely to adversely effect the health and efficiency of the recipients, and it would be an additional unnecessary disciplinary burden to enforce compliance, unlikely to succeed completely, particularly in the absence of an immediate credible threat of chemical attack.
At present, in order to take prophylactic drugs by mouth, the seal of the mask to the face must be opened, and special precautions taken to get the dosage into the mouth without introducing contamination.
It is not certain that the present arrangement is entirely safe, and it requires considerable training.
Various alternative solutions have been proposed including providing a water-proof coated single capsule held in the mouth and swallowed at the time of detection of chemical attack. The disadvantage of this is that the waterproof coating would delay or prevent absorption of the drug. If this type '`~
~m of capsule i9 bitten open at the time of cletection of chemical attack, the drug which i9 typically in loose powder form, would be released Lnto the mouth. Difficulty in 5wallowing without water ls the obvious disadvantage.
A capsule of this type i9 described in Canadian Patent No. 315,720, which issued 29 September 1931 to G.H. Lee et al.
According to the present invention a novel capaule assembly is provided, for oral administration of a prophylactic drug, said assembly com-prising an outer capsule of a suitable edible frangible material; a substan-tially uniform coating of a suitable edible material which is insoluble in digestive juices, on the exterior of said outer capsule; an inner capsule of a suitable edible material which is soluble in digestive juices, disposed within said outer capsule and containing an appropriate unit dosage of said prophylactic drug; and an airspace between said inner and outer capsules, arranged such that when said outer capsule is broken, the inner capsule is free to be swallowed intact.
The proposal is to provide a prophylactic drug mixture which would be held in reserve within the cheek pouch continuously whlle the chemical protective ensemble is worn in the open state (i.eO garment zipper open, mask in haversack, hood open, steel helmet worn).
In response to a liquid spray attack with an unidentified chemical agent, the ensemble would be closed immediately (i.e., mask donned, zipper closed, steel helmet replaced) according to the prescribed masking drill.
The action of biting open the outer capsule and swallowing the gelatin capsule containing the drug mixture would be taken if, and only if the spray attack were identified as a nerve agent, whether by use of local detector papers, by central command based on more sophisticated detection systems, or by medical diagnosis of casualties. The biting action would take place with the protective ensemble remaining closed (mask on).
In the event of no identified nerve gas attack, the drug capsule would remain in the cheek, to be discarded and replaced by a fresh capsule at the time of unmasking or later. The presence of the capsule in the cheek does not prevent eating or drinking when unmasked.
`~
11~3Z87 In the drawing which serves to illustraLe the preferred embodiment of the invention, the fig~lre is a side elevation in section of the novel capsule assembly~
Referring specifically to the drawing, it i5 seen that the assembly comprises an outer capsule 10 of a suitable frangible edible material, inclu~
ding a tubular body portion 12 and an end closure cap 14. The outer capsule lO is sealed together by a substantially uniform coating 16 of a suitable edible materlal which is insoluble in digestive juices, on the exterior thereof. An inner capsule 18 of a suitable edible material which i8 soluble :~ 10 in digestive ~uices is provided within outer capsule 10. The inner capsule 18 contains an appropriate dosage of a prophylactic drug, typlcally in powder form. An air space 22 is provided between the inner and outer capsules and ;; is arranged such that when the outer capsule is broken by biting, the inner capgule i8 free to be swallowed intact.
Thus, the double capsule provides the drug dosage at the required time relative to the spray attack, and in a form which allows prompt and reliable absorption of the drug from the gastrointestinal tract into the blood stream.
It is important that absorption be prompt and reliable, so that the drug will arrive in the blood stream coincident with the onset of symptoms of nerve gas poisoning. For liquid nerve gas on bare skin, symptoms occur approximately 30 to 60 minutes after contact with a lethal dose.
The inner capsule, preferably made of gelatin, have two additional advantages: ta) they can be swallowed without a drink of water, which would not be immediately available to a man in a mask, and (b) the standard 2-piece gelatin capsules are readily available commercially and can be filled without access to manufacturing machinery. This enables double capsules to be made by hand quickly and cheaply.
The air space between the outer waterproof capsule and the inner gelatin capsule has two important functions: (a) it allows the gelatin capsule to emerge free of any coating, and undamaged, when the outer capsule ' .
is bitten open. The inner gelatin capA~llo i9 then ready to ~wallow wlthout water and (b) it allows sufficient clearance 80 tha~ standard commercial gelatin capsules can be loaded into the preformed outer capsule bodies by a simple hand operation.
It is intended that the outer capsule be bitten open, and the frag-ments chewed and swallowed after the inner gelatin capsule. The outer capsule must protect the inner gelatin capsule from the moisture and mechanical action of the mouth for a holding period at least equal to the maximum time expected for troops to remain masked. Ideally, the outer capsule should withstand a 12 hour holding period, and 6 hours would be the minimum acceptable. The capsules would be discarded and replaced after that time.
The outer capsule is designed intentionally to be sufficiently large, to prevent accidental swallowing without biting open.
The material of the body and cap of the outer capsule must be suffi-ciently frangible to break up on biting, to allow the inner gelatin capsule to be free to be swallowed intact. The fragments must then be chewable into small bits for swallowing, after the inner gelatin capsule has been swallowed.
The coating on the exterior surface of the outer capsule has the essential function of protecting the body of the outer capsule from the diges-tive juices in the mouth during the holding period. If this coating were not present, or if it leaks, the body of the outer capsule would disintegrate before the end of the holding period.
An additional function of the coating is to cement the cap to the body of the outer capsule. The coating material is preferably of an edible wax such as paraffin wax and beeswax. Carnauba wax is also contemplated.
; Since it has the advantage that it is recognized as being harmless when taken by mouth.
A test program has been carried out with civilian volunteer human subjects to determine:
(1) whether the prototype capsule assembly could be held in the mouth for 6 hours without interfering with normal eating and drinking;
, 11~3Z87
(2) whether the prototyl)a capHule nssembly tleterlor~tad or di8in-tegrated during the holding period; and
(3) whether the prototype capsule assembly could be opened by chewing, the inner capsule swallowed, and the residue chewed and swallowed by the volunteer subjects while wearing ~ protectlve mask.
METHODS
Volunteers who were in possession of a Canadian Forces protective mask, were recruited from the DRES General Volunteers list without further medical screening. All subjects were well acquainted with the circumstances o of and response to chemical attack, and the use of the mask.
- Each volunteer was given a capsule assembly, with the inner gelatin capsule empty; he was directed to hold the capsule in his mouth in his cheek continuously, for 6 hours if possible commencing at approximately 0900 hrs.
The volunteer was also asked to report to the trial director the time of occurrence of any softening or disintegration of the outer capsule. The volun-teers retained the capsule assemblies in the mouth while taking their customary mid-morning coffee and lunch.
At the end of the six-hour period, the assembly was examined for signs of deterioration, or was replaced if it had failed during the holding period. The volunteer then put on his protective mask and proceeded to bite open the outer capsule, to swallow the gelatin capsule, and to chew and swallow the remnants of the outer capsule.
RESULTS
The first three tests were carried out with prototype capsule assem-blies which had been given a single thin coat of wax i.e. about 0.02 inches, and had been stored at room temperature for approximately nine months. All - three softened and failed approximately 30 minutes after the start of the holding period.
Ten tests were carried out with capsule assemblies which has been freshly coated with a couble layer of wax i.e. about 0.03 inches. The results are shown in Table l; of the ten subjects, seven completed the 6-hour holding period with cap9ule as9emblies intact; the waterproofing failed in two cases and the capsule was unintentionally bitten in one case.
_ 5 _ ' Table 1 Summary of Capsule Holding Tests . _ Volunteer Capsule Holding Capsule Subject No. Time-hoursCondition .
Capsules with 1 0.5 soft thin (about 0.02 inches) wax ? 0.6 soft coatings 3 0.5 soft --
METHODS
Volunteers who were in possession of a Canadian Forces protective mask, were recruited from the DRES General Volunteers list without further medical screening. All subjects were well acquainted with the circumstances o of and response to chemical attack, and the use of the mask.
- Each volunteer was given a capsule assembly, with the inner gelatin capsule empty; he was directed to hold the capsule in his mouth in his cheek continuously, for 6 hours if possible commencing at approximately 0900 hrs.
The volunteer was also asked to report to the trial director the time of occurrence of any softening or disintegration of the outer capsule. The volun-teers retained the capsule assemblies in the mouth while taking their customary mid-morning coffee and lunch.
At the end of the six-hour period, the assembly was examined for signs of deterioration, or was replaced if it had failed during the holding period. The volunteer then put on his protective mask and proceeded to bite open the outer capsule, to swallow the gelatin capsule, and to chew and swallow the remnants of the outer capsule.
RESULTS
The first three tests were carried out with prototype capsule assem-blies which had been given a single thin coat of wax i.e. about 0.02 inches, and had been stored at room temperature for approximately nine months. All - three softened and failed approximately 30 minutes after the start of the holding period.
Ten tests were carried out with capsule assemblies which has been freshly coated with a couble layer of wax i.e. about 0.03 inches. The results are shown in Table l; of the ten subjects, seven completed the 6-hour holding period with cap9ule as9emblies intact; the waterproofing failed in two cases and the capsule was unintentionally bitten in one case.
_ 5 _ ' Table 1 Summary of Capsule Holding Tests . _ Volunteer Capsule Holding Capsule Subject No. Time-hoursCondition .
Capsules with 1 0.5 soft thin (about 0.02 inches) wax ? 0.6 soft coatings 3 0.5 soft --
4 6 intact 6 intact 6 5 soft Capsules with 7 6 intact thick(about 0.03 inches) wax 8 6 intact coatlngs 9 6 intact 6 intact 11 3bitten & soft~
12 6 intact 13 3.5 soft . _ .
subject accidentally bit capsule while eating.
Minor annoyance and slight discomfort was experienced in holding the assembly in the cheek for long periods, which was attributed to the size of the diametér of the assembly, rather than the length.
All thirteen subject were able to open an intact assembly by biting, while wearing a Canadian Armed Forces protective mask, and to swallow the gelatin capsule and the remnants of the outer capsule.
: .
11~3287 The results 9110W that capsllle~ conLaini~ ropllylactic drugs can be held in reserve in the mou~h for six hourc or longer, with no more than slight discomfort, and without preventing normal eating and drinking. It is concluded that the concept of initiating drug prophylaxis after completion of the masklng drill and confirmation of the presence of nerve gas, arld without removing mask or gloves, is technically feasible. It is also apparent that the useful lower limit of the thickness of the was coating is about 0.03 inches. The was coating cannot be too thick as to prevent biting ease. An operable thick-ness range of 0.03 - 0.06 inches is therefore contemplated.
The edible frangible material used for the outer capsule is prefer-ably a mixture of whole wheat flour and molasses, baked hard, and coated with paraffin wax. It i8 also contemplated to employ a white or colourless material instead of whole wheat flour, in order that the assemblies could be colour coded with food colouring, to identify the different dosage forms which may be required. Since the fibre content of whole wheat flour appears important in giving mechanical strength and good moulding qualities (a) bleached whole-wheat flour, (b) white flour with addition of pure cellulose powder could be used. Corn syrup could be used instead of molasses.
Preparation of Edible Material Molasses - 2 parts by volume Whole wheat flour - 4 parts by volume Heat molasses to boiling. Add flour portionwise, with thorough mixing to produce a homogeneous plastic mass. Form into a ball, and wrap in waxed paper and foil for preservation.
Fabrication of Edible Capsules and Caps Approximately 2 g. of the edible material is formed into a ball;
this is then formed with the fingers over a cylindrical brass mandrel of diameter slightly greater han the outside diameter of the gelatin capsule to be used: the material is molded to form a hollow cylindrical with one end closed. The mandrel with material molded on it is placed in a brass holder.
11~3Z8t7 The caps are made by forming approximately 3.0 g. of the edible composition into a drill-hole of suitable dlameter and depth in a brass block.
After moulding, the capsules and caps are heated to 350F. for 10 minutes, and allowed to cool to room temperature, before freeing from the brass forms. The edible pieces are then trimmed to final size by means oE a jeweler's saw.
Assembly and Waxing The outer surface of the capsules and caps are coated with melted paraffin or beeswax. The gelatin capsule containing the powdered drug in unit dosage form is placed loosely inside the edible outer capsule, and the cap is sealed on with melted wax. The seam between cap and capsule is now smoothed by sandpapering away any rough edges, and a final coat of hot wax is applied with a brush. The outer capsule could be pre-coated wlth wax before final assembly.
The following prophylactic drugs adapted for oral administration are contemplated.
(1) A reversible cholinesterase inhibitor, for example Pyridostigmine Bromide, dose 30 to 60 mg.
(2) A peripllerally acting parasympatholytic drug, for example Propantheline Bromide, dose 15 to 30 mg.
(3~ A benzodiazepine tranquillizer, with anticonvulsant properties against nerve gas convulsions, for example, Diazepam, does 5 to 10 mg.
; (Note. The dosage has been shown as a range, because dose may be varied with body weight. All drugs to be powders) (4) A comblnation of tuo or tllre~ of the drubt meDtionod above.
_ ~ _
12 6 intact 13 3.5 soft . _ .
subject accidentally bit capsule while eating.
Minor annoyance and slight discomfort was experienced in holding the assembly in the cheek for long periods, which was attributed to the size of the diametér of the assembly, rather than the length.
All thirteen subject were able to open an intact assembly by biting, while wearing a Canadian Armed Forces protective mask, and to swallow the gelatin capsule and the remnants of the outer capsule.
: .
11~3287 The results 9110W that capsllle~ conLaini~ ropllylactic drugs can be held in reserve in the mou~h for six hourc or longer, with no more than slight discomfort, and without preventing normal eating and drinking. It is concluded that the concept of initiating drug prophylaxis after completion of the masklng drill and confirmation of the presence of nerve gas, arld without removing mask or gloves, is technically feasible. It is also apparent that the useful lower limit of the thickness of the was coating is about 0.03 inches. The was coating cannot be too thick as to prevent biting ease. An operable thick-ness range of 0.03 - 0.06 inches is therefore contemplated.
The edible frangible material used for the outer capsule is prefer-ably a mixture of whole wheat flour and molasses, baked hard, and coated with paraffin wax. It i8 also contemplated to employ a white or colourless material instead of whole wheat flour, in order that the assemblies could be colour coded with food colouring, to identify the different dosage forms which may be required. Since the fibre content of whole wheat flour appears important in giving mechanical strength and good moulding qualities (a) bleached whole-wheat flour, (b) white flour with addition of pure cellulose powder could be used. Corn syrup could be used instead of molasses.
Preparation of Edible Material Molasses - 2 parts by volume Whole wheat flour - 4 parts by volume Heat molasses to boiling. Add flour portionwise, with thorough mixing to produce a homogeneous plastic mass. Form into a ball, and wrap in waxed paper and foil for preservation.
Fabrication of Edible Capsules and Caps Approximately 2 g. of the edible material is formed into a ball;
this is then formed with the fingers over a cylindrical brass mandrel of diameter slightly greater han the outside diameter of the gelatin capsule to be used: the material is molded to form a hollow cylindrical with one end closed. The mandrel with material molded on it is placed in a brass holder.
11~3Z8t7 The caps are made by forming approximately 3.0 g. of the edible composition into a drill-hole of suitable dlameter and depth in a brass block.
After moulding, the capsules and caps are heated to 350F. for 10 minutes, and allowed to cool to room temperature, before freeing from the brass forms. The edible pieces are then trimmed to final size by means oE a jeweler's saw.
Assembly and Waxing The outer surface of the capsules and caps are coated with melted paraffin or beeswax. The gelatin capsule containing the powdered drug in unit dosage form is placed loosely inside the edible outer capsule, and the cap is sealed on with melted wax. The seam between cap and capsule is now smoothed by sandpapering away any rough edges, and a final coat of hot wax is applied with a brush. The outer capsule could be pre-coated wlth wax before final assembly.
The following prophylactic drugs adapted for oral administration are contemplated.
(1) A reversible cholinesterase inhibitor, for example Pyridostigmine Bromide, dose 30 to 60 mg.
(2) A peripllerally acting parasympatholytic drug, for example Propantheline Bromide, dose 15 to 30 mg.
(3~ A benzodiazepine tranquillizer, with anticonvulsant properties against nerve gas convulsions, for example, Diazepam, does 5 to 10 mg.
; (Note. The dosage has been shown as a range, because dose may be varied with body weight. All drugs to be powders) (4) A comblnation of tuo or tllre~ of the drubt meDtionod above.
_ ~ _
Claims (7)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS
1. A capsule assembly, for oral administration of a prophylactic drug, comprising an outer capsule of a suitable edible frangible material;
a substantially uniform coating of a suitable edible material which is insoluble in digestive juices, on the exterior of said outer capsule;
an inner capsule of a suitable edible material which is soluble in digestive juices, disposed within said outer capsule and containing an appro-priate unit dosage of said prophylactic drug; and an airspace between said inner and outer capsule, arranged such that when said outer capsule is broken, the inner capsule is free to be swallowed intact.
a substantially uniform coating of a suitable edible material which is insoluble in digestive juices, on the exterior of said outer capsule;
an inner capsule of a suitable edible material which is soluble in digestive juices, disposed within said outer capsule and containing an appro-priate unit dosage of said prophylactic drug; and an airspace between said inner and outer capsule, arranged such that when said outer capsule is broken, the inner capsule is free to be swallowed intact.
2. A capsule assembly according to claim 1, wherein said coating is of a wax selected from the group consisting of beeswax and paraffin wax.
3. A capsule assembly according to claim 2, wherein the thickness of said coating is 0.03 to 0.06 inches.
4. A capsule assembly according to claim 3, wherein said inner capsule is made of gelatin.
5. A capsule assembly according to claim 4, wherein the thickness of the wax coating is about 0.03 inches.
6. A capsule assembly according to claim 4, wherein said outer capsule is made of a mixture of 4 parts by volume of whole wheat flour and 2 parts by volume of molasses, baked hard.
7. A capsule assembly according to claim 1, 3 or 4, wherein said prophy-lactic drug is selected from the group consisting of a reversible cholinester-ase inhibitor, a periphally acting parasympatholytic drug, a benzodiazepine tranquillizer, with anti convulsant properties and mixtures thereof.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000383662A CA1143287A (en) | 1981-08-11 | 1981-08-11 | Waterproof edible encapsulation for prophylactic drugs |
| GB8218819A GB2103564B (en) | 1981-08-11 | 1982-06-29 | Compound capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000383662A CA1143287A (en) | 1981-08-11 | 1981-08-11 | Waterproof edible encapsulation for prophylactic drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1143287A true CA1143287A (en) | 1983-03-22 |
Family
ID=4120667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000383662A Expired CA1143287A (en) | 1981-08-11 | 1981-08-11 | Waterproof edible encapsulation for prophylactic drugs |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA1143287A (en) |
| GB (1) | GB2103564B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2253200A (en) * | 1991-02-01 | 1992-09-02 | Harris Pharma Ltd | Inhalation apparatus and fracturable capsule for use therewith |
| IT1296980B1 (en) | 1997-12-17 | 1999-08-03 | Istituto Pirri S R L | DOUBLE CAPSULE AS A PHARMACEUTICAL FORM FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS IN MULTIPLE THERAPIES |
| GB0017673D0 (en) * | 2000-07-20 | 2000-09-06 | Mw Encap Limited | Delivery device |
| US7670612B2 (en) | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
| CN115813878B (en) * | 2022-12-09 | 2024-06-28 | 浙江省食品药品检验研究院 | Waterproof coating solution and application thereof in preparation of waterproof capsules |
-
1981
- 1981-08-11 CA CA000383662A patent/CA1143287A/en not_active Expired
-
1982
- 1982-06-29 GB GB8218819A patent/GB2103564B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| GB2103564A (en) | 1983-02-23 |
| GB2103564B (en) | 1985-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6491037B1 (en) | Temperature indicating mouth guard | |
| US4870959A (en) | Protective breathing mask | |
| US3536074A (en) | Oral administration of a pill,tablet or capsule | |
| AU633394B2 (en) | Dual subcoated simulated capsule-like medicament | |
| US5770225A (en) | Process of preparing a subcoated simulated capsule-like medicament | |
| US5409709A (en) | Antipyretic analgesic preparation containing ibuprofen | |
| CA1143287A (en) | Waterproof edible encapsulation for prophylactic drugs | |
| BG49155A3 (en) | Capsules for medicinal forms and method for obtaining them | |
| US5456919A (en) | Capsule and caplet combination | |
| IL90910A (en) | Pharmaceutical composition for the prevention of sexually transmissable diseases | |
| AU678858B2 (en) | Controlled release potassium dosage form | |
| CA2124145A1 (en) | Combination Helmet and Body Protection Device | |
| AU2004201228C1 (en) | Compositions Including a Visual Marker and Method of Use Thereof | |
| AU672754B2 (en) | Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor | |
| GB2084016A (en) | Tablets containing desiccants | |
| US20080132830A1 (en) | Separable solid dosage form administration system | |
| JPH0729916B2 (en) | Pharmaceutical composition having analgesic properties | |
| EP0435726B1 (en) | Capsule and caplet combination | |
| EP0822810B1 (en) | Tamper evident pharmaceutical dosage form | |
| JP2008543851A (en) | Emetic capsules | |
| AU610582B2 (en) | Arrangement for and method of administering a pharmaceutical preparation | |
| CN112791046B (en) | Medicinal preparation with child safety protection function and use method | |
| CN112367978A (en) | Chewing gum comprising nicotine | |
| AU687420B2 (en) | Soft-shelled gelatin encapsulated particles | |
| Sheet | Kratom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |